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Objective: To compare the effectiveness, in terms of complete abortion, of the World 
Health Organization (WHO)- and the China-recommended protocol for first-trimester 
medical abortion.
Methods: A retrospective analysis of clinical data from women presenting for first trimester 
medical abortion between January 2009 and August 2010 at reproductive health clinics in 
Qingdao, Xi’an, Nanjing, Nanning, and Zhengzhou was conducted. One clinic in Qingdao 
administered the WHO-recommended protocol (200 mg mifepristone orally followed by 
0.8 mg misoprostol buccally 36–48 hours later). Four clinics in the other locations provided 
the China-recommended procedure (Day 1: 50 mg of mifepristone in the morning, 25 mg in 
the afternoon; Day 2: 50 mg of mifepristone in the morning, 25 mg in the afternoon; Day 3: 
0.6 mg oral misoprostol). Data on reproductive and demographic characteristics were extracted 
from clinic records, and complete termination was determined on day 14 (post-mifepristone 
administration).
Results: A total of 337 women underwent early medical abortion (167 WHO- and 170 China-
recommended procedures). Complete abortion was significantly higher among women who had 
the WHO protocol than those who received the China protocol (91.0% vs 77.7%, respectively; 
P , 0.001). Women using the China-recommended protocol were three times more likely to 
require an additional dose of misoprostol than women using the WHO protocol (21.8% vs 7.8%, 
respectively; P , 0.001), and had significantly more bleeding on the day of misoprostol 
  administration (12.5 mL vs 18.5 mL; P , 0.001).
Conclusion: This clinical audit provides preliminary evidence suggesting the WHO-
  recommended protocol may be more effective than the China-recommended protocol for early 
medical abortion. A larger scale study is necessary to compare the methods’ effectiveness and 
acceptability.
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Introduction
Since the synthesis of prostaglandins in 19691 and antiprogestogen in the 1980s,2 
mifepristone–misoprostol medical abortion has provided an important alternative 
to surgical methods for elective termination of pregnancy. Many studies have been 
conducted to identify better ways to deliver medical abortion methods, including the 
use of single drugs, varying the timing and routes of administration, and the use of 
different dose regimens.3–7 The World Health Organization (WHO) recommends the 
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combination of 200 mg mifepristone followed by 0.8 mg 
misoprostol 36–48 hours later for first-trimester termination 
(gestations up to 63 days since last menstrual period).8 This 
regimen results in $96% complete abortion, and #1% 
continuing pregnancy.2
Different combinations of mifepristone and misoprostol 
are being used in various settings.9 In 2005, the majority 
(84.6%; 22 million) of the 26 million women who used a 
mifepristone-misoprostol regimen to terminate an unintended 
pregnancy lived in China.10 Since the approval of mifepristone 
as an abortifacient in 1988, the widely accepted medical 
abortion protocol in China comprised 150 mg mifepristone 
administered in four small doses across 2 days (Day 1: 50 mg 
of mifepristone in the morning (AM), 25 mg in the afternoon 
(PM); Day 2: 50 mg of mifepristone in the AM, 25 mg in the 
PM), followed by 0.6 mg oral misoprostol on the third day.11 
Approximately two million women in China use this regimen 
annually,1 with high reported success rates (90%–97%) and 
client satisfaction ($80%).11
Although the WHO- and China-recommended medical 
abortion protocols have been used by millions of women for 
early termination, there has been no direct comparison of the 
effectiveness of these two methods. It is unclear whether 
the lower dose of misoprostol affects the effectiveness of 
the Chinese method. It is also unknown whether there is any 
difference in the clinical process, in terms of duration of the 
procedure and the amount of bleeding.
A retrospective analysis of clinical data was conducted 
to compare the effectiveness of the WHO- and China-
recommended medical abortion protocols for first-trimester 
termination of pregnancy at Marie Stopes International China 
(MSI China) clinics located in Qingdao, Xi’an, Nanjing, 
Nanning, and Zhengzhou.
Material and methods
Retrospective data from women presenting for first-tri-
mester medical abortion at MSI China clinics in Qingdao, 
Xi’an, Nanjing, Nanning, and Zhengzhou, between Janu-
ary 2009 and August 2010, were analyzed. Gestational age 
was determined by last menstrual period and ultrasound. 
Women with a known allergy to either mifepristone or 
misoprostol, suspicion of ectopic   pregnancy, chronic adre-
nal failure, concurrent long-term corticosteroid therapy, 
history of hemorrhagic disorders, concurrent anticoagulant 
therapy, or inherited porphyria were ineligible for medical 
terminations.
The MSI China clinic located in Qingdao administered 
the WHO-recommended medical abortion protocol, while 
the four clinics in Xi’an, Nanjing, Nanning, and Zhengzhou 
provided the Chinese-recommended procedure. Because this 
was a pilot phase of introducing the WHO-recommended 
medical regimen, only clinical staff at Qingdao were trained 
to deliver the protocol.
These five clinics were chosen because they are operated 
by MSI China. Prior to the medical abortion procedure, 
women’s characteristics including age, weight, number 
of births, number of pregnancies, and diameter of the 
sac tissue were recorded (per clinical standard practice). 
After informed consent was obtained, individuals who 
presented at the MSI China clinic in Qingdao underwent 
the WHO-recommended procedure, which consisted of 
200 mg oral mifepristone followed by 0.8 mg of buccal 
misoprostol 36–48 hours later. If no bleeding occurred 
3 hours after misoprostol administration, an additional dose 
of 200 µg misoprostol was given buccally. If no bleeding 
was observed after a further 2 hours, one more dose of 
200 µg buccal misoprostol was administered. Women who 
accessed MSI China clinics in Xi’an, Nanjing,   Nanning, 
and Zhengzhou underwent the China-recommended 
  procedure: Day 1: 50 mg oral mifepristone in the AM, then 
25 mg in the PM; Day 2: 50 mg oral mifepristone in the 
AM, then 25 mg in the PM; Day 3: Oral administration of 
0.6 mg misoprostol. If no bleeding had occurred 3 hours 
after misoprostol administration, an additional dose of 
200 µg misoprostol was given orally. If no bleeding was 
observed after a further 2 hours, one more dose of 200 µg 
misoprostol was orally administered. Under both protocols, 
patients attended the clinic for mifepristone and misoprostol 
administration, and they remained at the clinic for 4 hours 
after the administration of misoprostol for observation 
before being discharged.
All women received counseling on potential side effects 
and 500 mg paracetamol for pain management, and a follow-
up appointment was scheduled for day 14 after the admin-
istration of mifepristone. Complete abortion was defined 
as passing of the products of conception without needing 
vacuum aspiration at the follow-up visit. At the 14-day 
follow-up visit, all women were assessed for the status of 
their abortion procedure by clinical examination and ultra-
sonography. Individuals with ongoing pregnancy, persistent 
nonviable pregnancy, or gestational sac were offered imme-
diate surgical evacuation. Those with retained products at 
the 14-day follow-up visit confirmed by transvaginal ultra-
sound were given surgical evacuation. In addition to com-
plete abortion, we analyzed the following information: (a) 
whether any additional doses of misoprostol were required;   
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(b) the time to expulsion of the gestational sac (in hours); 
and (c) the amount of bleeding on the day of misoprostol 
  administration. Blood was collected in a container and 
measured in milliliters (mL) at the clinic after misoprostol 
administration.
All available data were retrieved from clinic records. 
Data management and analysis were carried out using Stata 
software (v. 11; Stata Corp, College Station, TX). Char-
acteristics of the study participants and outcomes in each 
protocol group were compared using t-tests (for difference 
in means) and Z-tests (for difference in proportions). The 
primary outcome of this study was the proportion of success-
ful abortions (defined as complete evacuation of the uterine 
contents without recourse to surgery by day 14). Secondary 
outcomes including the duration of the procedure and the 
amount of bleeding were also assessed. No ethics approval 
was obtained because this was a clinical audit.
Results
Study participants’ characteristics
Of the 357 medical abortion cases that were seen in the five 
clinics between January 2009 and August 2010, 337 women 
with gestational ages up to 63 days were included in 
this   analysis. A total of 167 women received the WHO-
  recommended procedure at the clinic in Qingdao, and 
170 women underwent the Chinese-recommended protocol 
at clinics in Xi’an, Nanjing, Nanning, and Zhengzhou.
The characteristics of the women who received the WHO-
recommended protocol were similar to the women who 
received the China-recommended protocol in terms of age, 
weight, and gestational age (Table 1). On average, women 
receiving the WHO protocol had more previous pregnancies 
than those that underwent the China protocol (2.2 vs 1.8 
pregnancies; P = 0.009), and had a larger gestational sac 
(17.7 mm vs 15.9 mm; P = 0.02).
Medical abortion outcomes
Among all 337 cases, 84.3% achieved complete abortion. 
This success rate was significantly higher among women 
who received the WHO protocol compared to individuals 
who had the China procedure (91.0% vs 77.7%, respectively; 
P , 0.001) (Table 2).
Approximately 14.8% (n = 50 of 337) of women had no 
response 3 hours after taking the medical abortion drugs, and 
required an additional dose of misoprostol (200 µg). Women 
using the China protocol were three times more likely to 
require an additional dose of misoprostol than women using 
the WHO protocol (21.8% vs 7.8%, respectively; P , 0.001) 
(Table 2). Five women who underwent the China protocol 
(2.9%) still had no response 5 hours after the administra-
tion of misoprostol, and required a further additional dose 
of misoprostol (200 µg). No women in the WHO protocol 
group required a second additional dose.
There was no evidence of a difference in the time to 
expulsion of the gestational sac between women using the 
WHO protocol and those using the China-recommended pro-
tocol (3.1 hours vs 3.4 hours; P = 0.10) (Table 2).   However, 
women in the WHO protocol group had significantly less 
bleeding on the day of the procedure than women in the China 
protocol group (12.5 mL vs 18.5 mL; P , 0.001).
Discussion
This analysis provides preliminary results that the WHO-
recommended medical abortion protocol may be more effective 
than the China-recommended protocol for early medical 
abortion (gestations # 63 days). There is evidence suggesting 
that women using the WHO-recommended protocol require 
fewer supplementary doses of misoprostol than those using the 
Chinese regimen, and experience less bleeding.
There are several key differences between the two   protocols. 
First, a smaller dose of mifepristone is used in the China 
Table 1 Characteristics of women, by medical abortion protocol
Characteristics 
Mean ± standard deviation
Medical abortion protocol P-value from t-test
World Health Organization- 
recommended*
China-recommended**
n  167 170
Age (years) 24.2 ± 4.5 23.3 ± 4.7 0.09
Weight (kg) 50.9 ± 7.1 49.8 ± 5.6 0.13
Number of pregnancies 2.2 ± 1.5 1.8 ± 1.1 0.009
Number of births 0.2 ± 0.5 0.1 ± 0.3 0.005
gestational age (days) 44.7 ± 5.4 43.7 ± 6.2 0.15
Diameter of gestational sac (mm) 17.7 ± 7.1 15.9 ± 7.6 0.02
Notes: *200 mg mifepristone followed by 800 µg misoprostol 36–48 hours later;14,15 **Day 1: 50 mg of mifepristone in the morning, 25 mg in the afternoon; Day 2: 50 mg 
of mifepristone in the morning, 25 mg in the afternoon; Day 3: 0.6 mg oral misoprostol.
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  protocol than in the WHO protocol (150 mg vs 200 mg). 
However, a study conducted in nine countries among more 
than 2000 women showed similar efficacy in achieving com-
plete abortion using 100 mg mifepristone compared to 200 mg 
mifepristone followed by misoprostol.12 Second, the dosing 
schedule is more complex within the China-recommended 
protocol, with mifepristone taken in four small doses over 
2 days, rather than in a single dose. Information on compli-
ance with the protocol was not available in this audit, there-
fore the effect of the dosing intervals on compliance cannot 
be assessed. Third, a smaller dose of misoprostol is used in 
the standard China-recommended protocol compared to the 
WHO-recommended protocol (0.6 mg vs 0.8 mg, respectively). 
A trial of 2962 women comparing 0.4 mg with 0.8 mg miso-
prostol following 200 mg mifepristone showed higher risk of 
incomplete abortion and continuing pregnancy with the lower 
dose of misoprostol.13 Women who underwent the China-
recommended protocol took additional doses of misoprostol 
to achieve successful termination. Finally, the interval between 
mifepristone and misoprostol administration is 24 hours in the 
China protocol, compared to 36–48 hours in the WHO protocol. 
A previous study showed that the 24-and 48-hour intervals have 
similar efficacy.12 In addition, women who received the WHO-
recommended regimen underwent buccal administration of 
misoprostol while individuals within the China-recommended 
group received oral administration of misoprostol. A recent 
Cochrane review showed that misoprostol administered orally 
is less effective than other routes of administration.14
There are limitations to this analysis. Due to the nature of a 
clinical audit with practical and resource constraints, there was 
no rigorous sampling strategy or random allocation of women 
to groups. However, the basic demographic characteristics 
for women in both groups were similar, and contamination 
between the two medical abortion protocols was minimized 
because the clinic in Qingdao exclusively provided the WHO-
recommended protocol while the other four clinics adminis-
tered the China-recommended protocol. Providers at all health 
facilities underwent the same termination service training for 
each protocol. The small number of study participants in this 
study limits the generalizability of the results.
While we were able to collect women’s demographic 
information and clinical indications, information on compli-
ance and women’s satisfaction were not available from the 
clinic record. Data on compliance to the protocol could reveal 
the effect of more complex dosing schedules on women’s 
ability to adhere to the protocols and health care providers’ 
confidence to deliver medical abortion regimens. Information 
on women’s satisfaction would provide important measures 
of the acceptability of each regimen. Reducing the number 
of doses within the China-recommended protocol is one pos-
sible way to simplify the provision of medical abortion. Stud-
ies from various settings which reduced the number of clinic 
visits through home-based administration of misoprostol 
showed high   acceptability (84%–96% acceptable).15–25 
Finally, this clinical audit was not able to obtain information 
on side effects such as diarrhea and vomiting from the clinic 
records, which may be important factors for acceptability of 
regimens.
Our analysis provides preliminary evidence suggesting 
greater effectiveness of the WHO-recommended p  rotocol 
for first-trimester medical abortion compared to the 
  China-recommended regimen. However, this was not 
Table 2 Proportion of complete abortion and details of medical abortion process, by protocol
Medical abortion protocol P-value for difference
World Health Organization-
recommended*
China-recommended**
n  167 170
Outcome
Complete abortion 
% (n)
91.0 (152) 77.7 (132) ,0.001
Procedure details
Required one additional dose of misoprostol 
% (n)
7.8 (13) 21.8 (37) ,0.001
Required two additional doses of misoprostol 
% (n)
0 2.9 (5) 0.03
Time to expulsion of gestational sac (hours) 3.1 ± 1.6 3.4 ± 1.4 0.10
Estimated amount of bleeding after misoprostol  
administration (mL)
12.5 ± 7.0 18.5 ± 13.6 ,0.001
Notes: *200 mg mifepristone followed by 800 µg misoprostol 36–48 hours later;14,15 **Day 1: 50 mg of mifepristone in the morning, 25 mg in the afternoon; Day 2: 50 mg 
of mifepristone in the morning, 25 mg in the afternoon; Day 3: 0.6 mg oral misoprostol.11
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a   randomized controlled trial, and the results must be 
interpreted with caution. Given the wide usage of both 
protocols in China, a larger scale study to compare their 
effectiveness and acceptability would be appropriate in the 
future.   Furthermore, analysis of the cost-effectiveness of each 
protocol may help to inform policy in China.
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